secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2025-05-16T23:59:59+00:00
Accession:  0000950170-25-073555
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax names Dr. Nicholas Botwood Head of R&D and CMO, replacing Neil Gallagher
-------------------------------------------------------------------------------

- Dr. Nicholas Botwood appointed Head of R&D and CMO, effective May 12, 2025; succeeds Dr. Neil Gallagher who is departing.
- Botwood most recently SVP, Head of Worldwide Medical Oncology at BMS; brings 25+ years oncology development experience.
- Employment terms: base salary $540K, annual target bonus 45%, stock option for 215K shares, PRSU of 23,400 units.
- Gallagher will remain for interim transition period; thanked for contributions including two product approvals.
- Annual meeting results: all director nominees elected, say-on-pay approved (62.5M for), auditor ratified.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000095017025073555/0000950170-25-073555-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000095017025073555/sndx-20250512.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-073555

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer